MicroTransponder: The company raised $73 million of Series E2 venture funding in a deal led by US Venture Partners on September 21, 2022, putting the company’s pre-money valuation at $72 million. The company is a developer of nerve stimulation-based therapies intended to treat stroke rehabilitation, tinnitus, and other neurological conditions.
EchoNous: The company received $57.5 million of development capital from undisclosed investors on September 23, 2022. The company is a developer of AI-guided ultrasound systems and software intended to solve common everyday problems in healthcare.
Naveris: The company raised $51 million of Series A venture funding in a deal led by Gurnet Point Capital on September 19, 2022, putting the company’s pre-money valuation at $27 million. The company is a developer of a blood test technology designed to detect specific subtypes of cancer and improve patient outcomes.
Ceribell: The company raised $49.4 million of Series C1 venture funding in a deal led by Ally Bridge Group on September 21, 2022, putting the company’s pre-money valuation at $253 million. Other undisclosed investors also invested in the round. The company is a developer of an EEG system intended to improve the diagnosis and treatment of patients at risk of seizures.
Incepto: The company raised EUR 27 million of venture funding in a deal led by LBO France on September 19, 2022. The company is a developer of artificial intelligence (AI) based medical imaging applications designed to offer computed tomography scans, chest x-ray, and detections for conditions such as fracture and bowel occlusion.
Nanolive: The company raised CHF 22.2 million of Series C1 venture funding in a deal led by Taiwania Capital on September 20, 2022, putting the company’s pre-money valuation at an estimated CHF 47.58 million. The company is a developer of a precision microscopic technology designed to capture dynamic, unbiased live cell data to accelerate discovery, development, and therapeutics.
March Therapeutics: The company raised $20.3 million of venture funding from undisclosed investors on September 21, 2022. The company is an operator of a biotechnology business intended to provide multiple genome-based services.
ABK Biomedical: The company raised $18.1 million of venture funding from undisclosed investors on September 22, 2022. The company is a developer of a microspheres product designed to improve the treatment of hypervascular tumors.
Elucidata: The company raised $16 million of Series A venture funding in a deal led by Eight Roads on September 21, 2022. The company is a developer of a data analytics platform designed to analyze omics datasets to understand the molecular basis of cellular phenotypes.
Quinten Health: The company raised EUR 14 million of venture funding from Techlife Capital and MACSF Ventures on September 21, 2022. The company is a developer of integrated care and precision medicine solutions intended for treatments and patient care using AI and real-world data science.
Nico Corporation: The company raised $12.6 million of venture funding from undisclosed investors on September 21, 2022. The company is a developer of minimally invasive surgical devices designed to be used in neurosurgery.
Elevation Spine: The company raised $11 million of Series B venture funding in a deal led by Technology Venture Partners on September 19, 2022. The company is a developer of interbody spinal fusion implants designed to be minimally invasive.
Embody: The company raised $10.4 million of Series C venture funding in a deal led by Genesis Innovation Group on September 20, 2022, putting the company’s pre-money valuation at $95 million. The company is a developer of implantable medical devices designed to improve the quality of life for traumatic and sports injury patients.
DocSpera: The company raised $9.6 million of venture funding from Johnson & Johnson Innovation – JJDC and Pier 70 Ventures on September 22, 2022. The company is a developer of an intelligent surgical planning platform intended to manage a patient from the surgical decision point through the end of recovery.
MicroHarvest: The company raised EUR 8.5 million of Series A venture funding in a deal led by Happiness Capital and Astanor Ventures on September 20, 2022. The company is an operator of a biotech business intended to produce nutrients and proteins made from bacteria.
THINK Surgical: The company raised $5.4 million of venture funding from Black Lake Expeditions on September 23, 2022. The company is a developer of a robotic surgical system intended to help improve the outcome of orthopedic surgery.
Leuko: The company raised $5 million of Series A venture funding in a deal led by Health Technology Holding on September 23, 2022. The company is a developer of a home-based neutrophil test designed to monitor and count white blood cells.
